WO2000027822A3 - Tricyclic pyrazole derivatives - Google Patents

Tricyclic pyrazole derivatives Download PDF

Info

Publication number
WO2000027822A3
WO2000027822A3 PCT/US1999/026105 US9926105W WO0027822A3 WO 2000027822 A3 WO2000027822 A3 WO 2000027822A3 US 9926105 W US9926105 W US 9926105W WO 0027822 A3 WO0027822 A3 WO 0027822A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazole derivatives
pyrazoles
tricyclic pyrazole
tricyclic
inhibitors
Prior art date
Application number
PCT/US1999/026105
Other languages
French (fr)
Other versions
WO2000027822A2 (en
Inventor
Kevin J Doyle
Paul Rafferty
Robert W Steele
David J Wilkins
Michael Hockley
Lee D Arnold
Anna M Ericsson
Original Assignee
Basf Ag
Kevin J Doyle
Paul Rafferty
Robert W Steele
David J Wilkins
Michael Hockley
Lee D Arnold
Anna M Ericsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020017005726A priority Critical patent/KR20010086005A/en
Priority to EP99962700A priority patent/EP1127051A2/en
Priority to BR9915132-4A priority patent/BR9915132A/en
Priority to JP2000581002A priority patent/JP2003517447A/en
Priority to IL14258499A priority patent/IL142584A0/en
Priority to CA002350235A priority patent/CA2350235A1/en
Priority to SK528-2001A priority patent/SK5282001A3/en
Priority to AU19091/00A priority patent/AU762992B2/en
Application filed by Basf Ag, Kevin J Doyle, Paul Rafferty, Robert W Steele, David J Wilkins, Michael Hockley, Lee D Arnold, Anna M Ericsson filed Critical Basf Ag
Priority to US09/573,366 priority patent/US6462036B1/en
Publication of WO2000027822A2 publication Critical patent/WO2000027822A2/en
Publication of WO2000027822A3 publication Critical patent/WO2000027822A3/en
Priority to BG105481A priority patent/BG105481A/en
Priority to NO20012219A priority patent/NO20012219L/en
Priority to HK02104091.8A priority patent/HK1042895A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.
PCT/US1999/026105 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives WO2000027822A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SK528-2001A SK5282001A3 (en) 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives
BR9915132-4A BR9915132A (en) 1998-11-06 1999-11-04 Method for inhibiting protein kinase activity, compounds of formula i and pharmaceutically acceptable salts thereof, use of the same, and pharmaceutical composition.
JP2000581002A JP2003517447A (en) 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives
IL14258499A IL142584A0 (en) 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives
CA002350235A CA2350235A1 (en) 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives
KR1020017005726A KR20010086005A (en) 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives
AU19091/00A AU762992B2 (en) 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives
EP99962700A EP1127051A2 (en) 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives
US09/573,366 US6462036B1 (en) 1998-11-06 2000-05-17 Tricyclic pyrazole derivatives
BG105481A BG105481A (en) 1998-11-06 2001-04-27 Tricyclic pyrazole derivatives
NO20012219A NO20012219L (en) 1998-11-06 2001-05-04 Tricyclic pyrazole derivatives
HK02104091.8A HK1042895A1 (en) 1998-11-06 2002-05-31 Tricyclic pyrazole derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10746798P 1998-11-06 1998-11-06
US60/107,467 1998-11-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/573,366 Continuation-In-Part US6462036B1 (en) 1998-11-06 2000-05-17 Tricyclic pyrazole derivatives

Publications (2)

Publication Number Publication Date
WO2000027822A2 WO2000027822A2 (en) 2000-05-18
WO2000027822A3 true WO2000027822A3 (en) 2000-08-10

Family

ID=22316761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026105 WO2000027822A2 (en) 1998-11-06 1999-11-04 Tricyclic pyrazole derivatives

Country Status (19)

Country Link
EP (1) EP1127051A2 (en)
JP (1) JP2003517447A (en)
KR (1) KR20010086005A (en)
CN (1) CN1335836A (en)
AU (1) AU762992B2 (en)
BG (1) BG105481A (en)
BR (1) BR9915132A (en)
CA (1) CA2350235A1 (en)
CZ (1) CZ20011563A3 (en)
HK (1) HK1042895A1 (en)
HU (1) HUP0200310A3 (en)
ID (1) ID30132A (en)
IL (1) IL142584A0 (en)
NO (1) NO20012219L (en)
PL (1) PL348210A1 (en)
SK (1) SK5282001A3 (en)
TR (1) TR200102277T2 (en)
WO (1) WO2000027822A2 (en)
ZA (1) ZA200103610B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9566290B2 (en) 2005-02-16 2017-02-14 Anacor Pharmaceuticals, Inc. Boron-containing small molecules

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
US6414011B1 (en) * 1999-03-26 2002-07-02 Euro-Celtique S.A. Aryl substituted pyrazoles, and pyrroles, and the use thereof
NZ514269A (en) * 1999-04-06 2003-10-31 Abbott Gmbh & Co Substituted 1,4-dihydroindeno[1,2-c]pyrazoles useful as inhibitors of tyrosine kinase
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
WO2001077171A2 (en) 2000-04-05 2001-10-18 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
US6723730B2 (en) 2000-07-20 2004-04-20 Neurogen Corporation Capsaicin receptor ligands
ATE295354T1 (en) * 2000-08-18 2005-05-15 Agouron Pharma HETEROCYCLIC HYDROXIMINO FLUORENES AND THEIR USE FOR INHIBITING PROTEIN KINASES
CA2430376A1 (en) * 2000-12-08 2002-06-13 David J. Carini Semicarbazides and their uses as cyclin dependent kinase inhibitors
BR0212611A (en) 2001-09-19 2004-08-17 Pharmacia Corp Substituted pyrazolyl compounds for the treatment of inflammation
US6849653B2 (en) 2001-09-19 2005-02-01 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
MXPA04008680A (en) * 2002-02-19 2004-12-06 Pharmacia Italia Spa Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents.
US20060264493A1 (en) * 2003-02-17 2006-11-23 Ermes Vanotti Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7456169B2 (en) 2003-02-27 2008-11-25 Abbott Laboratories Inc. Heterocyclic kinase inhibitors
CA2517885A1 (en) * 2003-03-07 2004-09-23 Abbott Laboratories Fused tri and tetra-cyclic pyrazole kinase inhibitors
US7320986B2 (en) 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
JP5064795B2 (en) * 2003-04-07 2012-10-31 アジェニックス ユーエスエー インク． Inhibitors, compositions, and related uses for cyclin-dependent kinases
AR045037A1 (en) 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7468371B2 (en) 2004-03-24 2008-12-23 Abbott Laboratories Inc. Tricyclic pyrazole kinase inhibitors
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
NZ560448A (en) 2005-02-16 2009-08-28 Anacor Pharmaceuticals Inc Boron-containing small molecules
JP2009519974A (en) * 2005-12-16 2009-05-21 ジェネンテック・インコーポレーテッド Tetracyclic kinase inhibitor
DK1988779T5 (en) * 2006-02-16 2016-10-10 Anacor Pharmaceuticals Inc SMALL boron MOLECULES AS ANTI-INFLAMMATORY AGENTS
EA200802058A1 (en) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. DERIVATIVES OF CYCLO-ALKYLAMINO ACIDS AND THEIR PHARMACEUTICAL COMPOSITIONS
RU2547441C2 (en) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Boron-containing small molecules as anti-inflammatory agents
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Boron-containing small molecules
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011059784A1 (en) 2009-10-29 2011-05-19 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
US8461134B2 (en) 2009-11-11 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8623911B2 (en) 2010-03-19 2014-01-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
SG10201507032YA (en) 2010-09-07 2015-10-29 Anacor Pharmaceuticals Inc Benzoxaborole derivatives for treating bacterial infections
US8853207B2 (en) 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
CN102675326B (en) * 2012-04-26 2014-08-20 华东理工大学 Preparation method of 3,4-dihydrobenzene benzopyran [3,4-c] pyrazole tricyclic compound
EP2909212B1 (en) * 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
US9497970B2 (en) * 2013-07-15 2016-11-22 Basf Se Pesticide compounds
WO2016113261A1 (en) * 2015-01-13 2016-07-21 Basf Se Fused tricyclic compounds, compositions comprising these compounds and their use for con-trolling invertebrate pests
CN105884828A (en) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 Polycyclic compound, pharmaceutical composition and application thereof
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
BR112019010629B1 (en) 2016-11-28 2022-11-01 Sumitomo Chemical Company, Limited COMPOUND, METHOD FOR CONTROLLING A PEST, USE OF THE COMPOUND, AND COMPOSITION
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Alkylphenyl compounds
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
WO2021115560A1 (en) * 2019-12-09 2021-06-17 Rottapharm Biotech S.R.L. New fyn and vegfr2 kinase inhibitors
CN113773258B (en) * 2020-06-09 2023-08-25 兰州大学 Human LRRK2 protein small molecule inhibitor and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
JPS60130521A (en) * 1983-12-19 1985-07-12 Morishita Seiyaku Kk Anticancer agent
WO1997015308A1 (en) * 1995-10-23 1997-05-01 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
WO1999017770A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
WO1999017769A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
JPS60130521A (en) * 1983-12-19 1985-07-12 Morishita Seiyaku Kk Anticancer agent
WO1997015308A1 (en) * 1995-10-23 1997-05-01 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
WO1999017770A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
WO1999017769A1 (en) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft INDENO[1,2-c]-, NAPHTHO[1,2-c]- AND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLE DERIVATIVES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198534, Derwent World Patents Index; Class B02, AN 1985-206644, XP002136705 *
MOSHER; SOEDER: "3-Cycloalkyl- and 3-heterocyclic substituted indeno[1,2-c]pyrazol-4(1H)ones", JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 8, no. 5, 1971, HETEROCORPORATION. PROVO., US, pages 855 - 859, XP002136704, ISSN: 0022-152X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9566290B2 (en) 2005-02-16 2017-02-14 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9566289B2 (en) 2005-02-16 2017-02-14 Anacor Pharmaceuticals, Inc. Boron-containing small molecules

Also Published As

Publication number Publication date
TR200102277T2 (en) 2002-01-21
CZ20011563A3 (en) 2003-02-12
ID30132A (en) 2001-11-08
NO20012219D0 (en) 2001-05-04
CN1335836A (en) 2002-02-13
NO20012219L (en) 2001-06-13
PL348210A1 (en) 2002-05-06
ZA200103610B (en) 2002-09-23
HUP0200310A2 (en) 2002-11-28
CA2350235A1 (en) 2000-05-18
SK5282001A3 (en) 2002-01-07
HK1042895A1 (en) 2002-08-30
JP2003517447A (en) 2003-05-27
AU762992B2 (en) 2003-07-10
HUP0200310A3 (en) 2002-12-28
KR20010086005A (en) 2001-09-07
AU1909100A (en) 2000-05-29
BG105481A (en) 2001-12-29
BR9915132A (en) 2001-08-07
IL142584A0 (en) 2002-03-10
EP1127051A2 (en) 2001-08-29
WO2000027822A2 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
WO2000027822A3 (en) Tricyclic pyrazole derivatives
WO2001087846A3 (en) Tricyclic pyrazole derivatives as protein kinase inhibitors
DE69924480D1 (en) Pyrazolderivative als p-38 map kinase inhibitoren
WO2001032663A3 (en) Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
IL114315A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same for inhibiting phosphodiesterase IV
PL340412A1 (en) Bicyclic kinase inhibitors
CA2390649A1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
WO2003008407A3 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
RU93049108A (en) DERIVATIVES OF PYRAZOL, METHOD OF THEIR PRODUCTION, CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND INTERMEDIATE SYNTHESIS COMPOUNDS
HUP0103815A3 (en) Substituted pyrazole derivatives condensed with six-membered heterocyclic rings, process for their preparation and pharmaceutical compositions containing them
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
HUT77360A (en) Azole derivatives as apolipoprotein-b synthesis inhibitors, process for their preparation, pharmaceutical compositions containing the same and intermediates of them
BG106044A (en) Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
WO2001023392A8 (en) Tetracyclic benzimidazole derivatives and combinatorial libraries thereof
HUP9601321A3 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them their use as pharmaceutical compositions or diagnostica, and the use of the said compds.
WO2003097597A3 (en) Indole derivatives and the use thereof as cb2 receptor ligands
HUP9602640A3 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.
WO2002008227A3 (en) Bicyclic hydantoin derivatives and combinatorial libraries thereof
WO2000037465A3 (en) Novel derivatives of swainsonine, processes for their preparation, and their use as therapeutic agents
DE59914314D1 (en) 2,3,3a, 4,9,9a-HEXAHYDRO-8-HYDROXY-1H-BENZAFEINDLE, PROCESS FOR THEIR PREPARATION AND THEIR USE AS DRUG
ZA200006272B (en) Pyrazole derivatives as p-38 MAP kinase inhibitors.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99814744.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 09573366

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 142584

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 5282001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 1999 105481

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004211

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2350235

Country of ref document: CA

Ref document number: 2350235

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-1563

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2001/03610

Country of ref document: ZA

Ref document number: 511524

Country of ref document: NZ

Ref document number: 200103610

Country of ref document: ZA

Ref document number: 19091/00

Country of ref document: AU

Ref document number: IN/PCT/2001/627/CHE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2000 581002

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017005726

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999962700

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/02277

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1999962700

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017005726

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-1563

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 19091/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020017005726

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999962700

Country of ref document: EP